International Journal of Clinical Oncology

, Volume 18, Issue 5, pp 927–933 | Cite as

Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia

  • Antonio Ruggiero
  • Gabriella De Rosa
  • Daniela Rizzo
  • Andrea Leo
  • Palma Maurizi
  • Alessia De Nisco
  • Francesca Vendittelli
  • Cecilia Zuppi
  • Alvaro Mordente
  • Riccardo Riccardi
Original Article



Despite significant improvements in the prognosis of childhood acute lymphoblastic leukaemia (ALL), the risk of anthracycline-induced cardiovascular disease remains a major concern. This study was designed to investigate the role of the myocardial performance index (MPI) and serum concentrations of biomarkers (cTnT and NT-pro-BNP) in the early detection of subclinical anthracycline-induced functional alterations in children with ALL.


All children consecutively admitted to our Pediatric Oncologic Department from January 2009 to October 2010 with a diagnosis of ALL were enrolled in this study. cTnT and NT-pro-BNP were evaluated in all patients at diagnosis, before doxorubicin therapy and 2 and 24 h following each anthracycline administration. ECG and echocardiography were performed at diagnosis and 24 h after each anthracycline course.


Nineteen children with standard-risk ALL were evaluated. The mean age was 6 years. The cumulative doxorubicin dosage was 240 mg/m2 according to the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) ALL 2000 protocol. None of the 19 patients developed congestive heart failure. With increasing cumulative dosages of anthracyclines a significant increase was observed in MPI. This increase was statistically significant starting from the cumulative dosage of 120 mg/m2 compared to baseline, while the median NT-pro-BNP level did not change significantly during treatment and cTnT levels never exceeded the cut-off value for cardiac injury.


MPI value is a sensitive and accurate parameter, allowing subclinical cardiac dysfunction to be detected in children receiving anthracyclines. Lifelong cardiac surveillance of these patients is warranted in order to determine the clinical implications of increased MPI on long-term cardiac status.


Myocardial performance index Doxorubicin Cardiotoxicity Children Acute lymphoblastic leukaemia 


  1. 1.
    Rather M, Carlsen NL, Oxhøj H (2007) Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 48:663–667CrossRefGoogle Scholar
  2. 2.
    Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677PubMedCrossRefGoogle Scholar
  3. 3.
    van Dalen EC, van der Pal HJ, Kok WE et al (2006) Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 42:3191–3198PubMedCrossRefGoogle Scholar
  4. 4.
    Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302PubMedCrossRefGoogle Scholar
  5. 5.
    Eidem BW, Sapp BG, Suarez CR et al (2001) Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 87:1120–1122PubMedCrossRefGoogle Scholar
  6. 6.
    Belham M, Kruger A, Pritchard C (2006) The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. J Am Soc Echocardiogr 19:206–210PubMedCrossRefGoogle Scholar
  7. 7.
    Ishii M, Tsutsumi T, Himeno W et al (2000) Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol 86:1279–1281PubMedCrossRefGoogle Scholar
  8. 8.
    Sato T, Harada K, Tamura M et al (2001) Cardiorespiratory exercise capacity and its relation to a new Doppler index in children previously treated with anthracycline. J Am Soc Echocardiogr 14:256–263PubMedCrossRefGoogle Scholar
  9. 9.
    Ocal B, Oguz D, Karademir S et al (2002) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 23:522–527PubMedGoogle Scholar
  10. 10.
    Dodos F, Halbsguth T, Erdmann E et al (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97:318–326PubMedCrossRefGoogle Scholar
  11. 11.
    Herman EH, Zhang J, Lipshultz SE et al (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237–2243PubMedGoogle Scholar
  12. 12.
    Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153PubMedCrossRefGoogle Scholar
  13. 13.
    Lipshultz SE, Rifai N, Sallan SE et al (1997) Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641–2648PubMedCrossRefGoogle Scholar
  14. 14.
    Mavinkurve-Groothuis AM, Kapusta L, Nir A et al (2008) The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 25:655–664PubMedCrossRefGoogle Scholar
  15. 15.
    Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950–961PubMedCrossRefGoogle Scholar
  16. 16.
    Albers S, Mir TS, Haddad M et al (2006) N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 44:80–85PubMedCrossRefGoogle Scholar
  17. 17.
    Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463PubMedCrossRefGoogle Scholar
  18. 18.
    Ocal B, Oguz D, Karademir S et al (2003) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 23:522–527Google Scholar
  19. 19.
    Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879PubMedCrossRefGoogle Scholar
  20. 20.
    Wojtacki J, Lewicka-Nowak E, Leśniewski-Kmak K (2000) Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention—review of the literature. Med Sci Monit 6:411–420PubMedGoogle Scholar
  21. 21.
    Ruggiero A, Ridola V, Puma N et al (2008) Anthracycline cardiotoxicity in childhood. Pediatr Hematol Oncol 25:261–281PubMedCrossRefGoogle Scholar
  22. 22.
    Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest 65:128–135PubMedCrossRefGoogle Scholar
  23. 23.
    Rossi F, Filippelli W, Russo S et al (1994) Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol Toxicol 75:99–107PubMedCrossRefGoogle Scholar
  24. 24.
    Goormaghtigh E, Huart P, Praet M et al (1990) Structure of the doxorubicin-cardiolipin complex role in mitochondrial toxicity. Biophys Chem 35:247–257PubMedCrossRefGoogle Scholar
  25. 25.
    Huber SA (1990) Doxorubicin-induced alterations in cultured myocardial cells stimulate cytolytic T lymphocyte responses. Am J Pathol 137:449–456PubMedGoogle Scholar
  26. 26.
    Yeh ET, Tong AT, Lenihan DJ et al (2004) Cardiovascular complication of cancer therapy: diagnosis, pathogenesis and management. Circulation 109:3122–3131PubMedCrossRefGoogle Scholar
  27. 27.
    Kurz K, Voelker R, Zdunek D et al (2007) Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152–159PubMedCrossRefGoogle Scholar
  28. 28.
    Weber M, Kleine C, Keil E et al (2006) Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95:270–280PubMedCrossRefGoogle Scholar
  29. 29.
    Daugaard G, Lassen U, Bie P et al (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7:87–93PubMedCrossRefGoogle Scholar
  30. 30.
    Suzuki T, Hayashi D, Yamazaki T et al (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362–363PubMedCrossRefGoogle Scholar
  31. 31.
    Herman EH, Zhang J, Lipshultz SE et al (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237–2243PubMedGoogle Scholar
  32. 32.
    Fink FM, Genser N, Fink C et al (1995) Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 25:185–189PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2012

Authors and Affiliations

  • Antonio Ruggiero
    • 1
  • Gabriella De Rosa
    • 2
  • Daniela Rizzo
    • 1
  • Andrea Leo
    • 3
  • Palma Maurizi
    • 1
  • Alessia De Nisco
    • 2
  • Francesca Vendittelli
    • 4
  • Cecilia Zuppi
    • 4
  • Alvaro Mordente
    • 4
  • Riccardo Riccardi
    • 1
  1. 1.Pediatric Oncology Division, “A. Gemelli” HospitalCatholic University of RomeRomeItaly
  2. 2.Paediatric Cardiology, Department of Paediatrics, “A. Gemelli” HospitalCatholic UniversityRomeItaly
  3. 3.Cardiology Division, “A. Gemelli” HospitalCatholic UniversityRomeItaly
  4. 4.Institute of Biochemistry and Clinical Biochemistry“A. Gemelli” HospitalRomeItaly

Personalised recommendations